down arrow

Tempest Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US87978U1088
  • NASDAQ: MLND
USD
1.00
0.23 (29.23%)

Sep 22

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.781.08

52 Week

0.7412.23
Valuation
Technical
Day's Volume

CASH

217.26 k

Shareholding (Jun 2026)

FII

0.23%

Held by 13 FIIs

DII

97.53%

Held by 3 DIIs

Promoter

2.25%

Is Tempest Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Tempest Therapeutics, Inc. shows a bullish trend with mixed strength indicators, but it has significantly underperformed the S&P 500, with a 1-year return of -45.39% compared to 17.14% for the index.

As of 9 September 2025, the technical trend for Tempest Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, albeit with mixed strength indicators. The MACD shows mildly bullish signals on both weekly and monthly time frames, while the RSI indicates a bearish weekly stance but a bullish monthly one. The Bollinger Bands are mildly bullish weekly but bearish monthly, and the KST is bullish weekly while bearish monthly. The moving averages are mildly bearish on a daily basis. <BR><BR>Despite the bullish trend, the stock has significantly underperformed against the S&P 500 across multiple periods, with a 1-year return of -45.39% compared to the S&P 500's 17.14%, and a staggering 5-year return of -96.83% versus 96.61% for the benchmark.

View full answer

How big is Tempest Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Tempest Therapeutics, Inc. has a market capitalization of 28.00 million and reported net sales of 0.00 million with a net profit of -44.80 million over the last four quarters. As of Dec 24, the company's shareholder's funds were 19.13 million, and total assets amounted to 44.02 million.

As of Jun 18, Tempest Therapeutics, Inc. has a market capitalization of 28.00 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a consolidated net profit of -44.80 million during the same period.<BR><BR>As of Dec 24, the company's shareholder's funds were 19.13 million, and total assets amounted to 44.02 million.

View full answer

What does Tempest Therapeutics, Inc. do?

22-Jun-2025

Tempest Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing treatments for orphan endocrine diseases. It has a market cap of $28 million and reported a net profit loss of $11 million as of March 2025.

Overview:<BR>Tempest Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 28.00 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.46<BR>Return on Equity: -402.40%<BR>Price to Book: 2.51<BR><BR>Contact Details:<BR>Address: 110 Miller Ave Ste 100, ANN ARBOR MI: 48104-1305<BR>Tel: ['1 734 8459000', '1 734 8648006']<BR>Fax: 1 302 6555049<BR>Website: https://www.millendo.com/

View full answer

Who are in the management team of Tempest Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Tempest Therapeutics, Inc. includes Dr. Carol Gallagher as the Independent Chairman and Dr. Julia Owens as President and CEO, along with several Independent Directors: Mr. Habib Dable, Dr. Mary Hedley, Mr. James Hindman, Dr. John Howe, and Dr. Geoffrey Nichol.

As of March 2022, the management team of Tempest Therapeutics, Inc. includes Dr. Carol Gallagher, who serves as the Independent Chairman of the Board, and Dr. Julia Owens, who is the President, Chief Executive Officer, and a Director. Other members of the Board of Directors include Mr. Habib Dable, Dr. Mary Hedley, Mr. James Hindman, Dr. John Howe, and Dr. Geoffrey Nichol, all of whom are Independent Directors.

View full answer

Compare Tempest Therapeutics, Inc. with Similar Stocks

Petros Pharmaceuticals, Inc.Universe Pharmaceuticals, Inc.ZyVersa Therapeutics, Inc.
iScoreScore

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 23 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.00

stock-summary
Return on Equity

-568.14%

stock-summary
Price to Book

3.68

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2026)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-20.0%
0%
-20.0%
6 Months
-56.33%
0%
-56.33%
1 Year
-89.42%
0%
-89.42%
2 Years
-94.3%
0%
-94.3%
3 Years
158.4%
0%
158.4%
4 Years
-47.37%
0%
-47.37%
5 Years
-93.27%
0%
-93.27%

Tempest Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
2.39%
EBIT to Interest (avg)
-31.65
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.46
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.29%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.68
EV to EBIT
-0.47
EV to EBITDA
-0.47
EV to Capital Employed
-16.96
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-568.14%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (2.46%)

Foreign Institutions

Held by 13 Foreign Institutions (0.23%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2026 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2026 is 34.18% vs 17.71% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.20",
          "val2": "-7.90",
          "chgp": "34.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.20",
          "val2": "-7.90",
          "chgp": "34.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 37.08% vs -41.69% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.30",
          "val2": "-41.60",
          "chgp": "36.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "1.30",
          "chgp": "-84.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-26.30",
          "val2": "-41.80",
          "chgp": "37.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - YoYstock-summary

Jun'26
Jun'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-5.20
-7.90
34.18%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.20
-7.90
34.18%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2026 is 0.00% vs 0.00% in Jun 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2026 is 34.18% vs 17.71% in Jun 2025

All Quarterly Resultsstock-summary

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-26.30
-41.60
36.78%
Interest
0.20
1.30
-84.62%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-26.30
-41.80
37.08%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 37.08% vs -41.69% in Dec 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Tempest Therapeutics, Inc. stock-summary
stock-summary
Tempest Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Millendo Therapeutics, Inc., formerly OvaScience, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing novel treatments for orphan endocrine diseases. The Company is focused on advancing two product candidates to treat three indications. Its advanced product candidate, livoletide (AZP-531), is a potential treatment for Prader-Willi syndrome (PWS), which is a rare and complex genetic endocrine disease characterized by hyperphagia, or insatiable hunger. It is also developing nevanimibe (ATR-101) with a primary focus on treating patients with classic congenital adrenal hyperplasia (CAH), which is a rare, monogenic adrenal disease that requires lifelong treatment with exogenous cortisol.
Company Coordinates stock-summary
Company Details
110 Miller Ave Ste 100 , ANN ARBOR MI : 48104-1305
stock-summary
Tel: 1 734 84590001 734 8648006
stock-summary
https://www.millendo.com/
stock-summary
Registrar Details
Footer loading